| __timestamp | Agios Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 10337679 |
| Thursday, January 1, 2015 | 35992000 | 18187286 |
| Friday, January 1, 2016 | 50714000 | 24758063 |
| Sunday, January 1, 2017 | 71124000 | 23666957 |
| Monday, January 1, 2018 | 114145000 | 30099855 |
| Tuesday, January 1, 2019 | 132034000 | 64947625 |
| Wednesday, January 1, 2020 | 149070000 | 186363444 |
| Friday, January 1, 2021 | 121445000 | 272611040 |
| Saturday, January 1, 2022 | 121673000 | 358782000 |
| Sunday, January 1, 2023 | 119903000 | 409864000 |
| Monday, January 1, 2024 | 156784000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Intra-Cellular Therapies has seen a dramatic increase in SG&A expenses, rising from approximately $10 million in 2014 to over $400 million in 2023, marking a staggering 3,900% increase. In contrast, Agios Pharmaceuticals experienced a more modest growth of around 525%, with expenses increasing from $19 million to $120 million. This divergence highlights differing strategic priorities and operational scales. While Intra-Cellular Therapies has aggressively expanded its operational footprint, Agios Pharmaceuticals has maintained a steadier growth trajectory. Understanding these trends provides valuable insights into each company's strategic focus and market positioning.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.